Glaukos Q2 sales jump 50%; raises net sales forecast

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell".

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".

Wall Street's median 12-month price target for Glaukos Corp is $166.50, about 10% above its July 28 closing price of $151.33.

Glaukos raised its 2026 net sales guidance to $680 mln-$700 mln from $620 mln-$635 mln. The company said it expects strong growth momentum driven by iDose TR and Epioxa.

• Product launches - Glaukos said record results were driven by commercial execution of iDose TR and Epioxa.